Madison Jones

Madison Jones practices corporate and securities law, representing late-stage private and publicly traded companies and underwriters, with a particular emphasis on capital markets transactions within two of the most rapidly growing industries: technology and life sciences. She has extensive experience counseling clients on the full range of general corporate and securities matters, including IPOs, public offerings, strategic corporate relationships, SEC reporting and compliance and corporate governance.

Madison has been repeatedly recognized as a leading attorney, deal expert and trusted advisor who understands the intricacies of her clients’ industries and helps them navigate and solve complex challenges with a very practical, business-oriented approach.

Over the past five years, Madison has advised over 25 IPOs and public offerings, with an aggregate value greater than $7.1 billion.

Representative company-side and underwriter-side public offerings:

• PhaseBio Pharmaceuticals – $46 million IPO 
• Epizyme – aggregate $236 million for multiple follow-on offerings 
• Argenx – aggregate of $317.4 million IPO and follow-on offering
• Endava – $145.8 million IPO
• Tenable Holdings – $288.3 million IPO
• Liquidia Technologies – $50 million IPO
• Helius Medical – $16 million follow-on offering
• AveXis – aggregate of about $1 billion IPO and follow-on offerings
• Yext – $132.8 million IPO
• OrthoPediatrics – $59.8 million IPO
• Sucampo Pharmaceuticals – $300 million notes offering

Representative investment bank and underwriter clients:

• Cowen
• Jefferies
• J.P. Morgan
• Morgan Stanley
• Piper Jaffray
• Stifel

Representative mergers and acquisitions:

• Sucampo Pharmaceuticals – acquisition of Vtessse ($200 million)
• Cerecor – sale of CERC-501 to Janssen Pharmaceuticals ($25 million)
• AveXis – acquisition by Novartis ($8.7 billion)

Madison is also deeply committed to causes that drive equality, diversity and awareness nationally and internationally, and she has provided pro bono counsel to the National Center for Transgender Equality and the Ferguson Road Initiative. She is also an influencer in the education sphere, having served on the Duke Law Alumni Association Board of Directors from 2011 to 2016, and she contributes thought leadership and research papers for Harvard on corporate governance. While attending law school, Madison served as the Special Projects Editor of Law & Contemporary Problems.